GLORIA

GEOMAR Library Ocean Research Information Access

Ihre E-Mail wurde erfolgreich gesendet. Bitte prüfen Sie Ihren Maileingang.

Leider ist ein Fehler beim E-Mail-Versand aufgetreten. Bitte versuchen Sie es erneut.

Vorgang fortführen?

Exportieren
  • 1
    Online-Ressource
    Online-Ressource
    Frontiers Media SA ; 2022
    In:  Frontiers in Oncology Vol. 12 ( 2022-6-27)
    In: Frontiers in Oncology, Frontiers Media SA, Vol. 12 ( 2022-6-27)
    Kurzfassung: The outcomes of myelodysplastic syndrome (MDS) patients with SF3B1 mutation, despite identified as a favorable prognostic biomarker, are variable. To comprehend the heterogeneity in clinical characteristics and outcomes, we reviewed 140 MDS patients with SF3B1 mutation in Zhejiang province of China. Seventy-three (52.1%) patients diagnosed as MDS with ring sideroblasts (MDS-RS) following the 2016 World Health Organization (WHO) classification and 118 (84.3%) patients belonged to lower risk following the revised International Prognostic Scoring System (IPSS-R). Although clonal hematopoiesis-associated mutations containing TET2 , ASXL1 and DNMT3A were the most frequent co-mutant genes in these patients, RUNX1, EZH2, NF1 and KRAS/NRAS mutations had significant effects on overall survival (OS). Based on that we developed a risk scoring model as IPSS-R×0.4+ RUNX1 ×1.1+ EZH2 ×0.6+ RAS ×0.9+ NF1 ×1.6. Patients were categorized into two subgroups: low-risk (L-R, score & lt;= 1.4) group and high risk (H-R, score & gt; 1.4) group. The 3-year OS for the L-R and H-R groups was 91.88% (95% CI, 83.27%-100%) and 38.14% (95% CI, 24.08%-60.40%), respectively (P & lt;0.001). This proposed model distinctly outperformed the widely used IPSS-R. In summary, we constructed and validated a personalized prediction model of MDS patients with SF3B1 mutation that can better predict the survival of these patients.
    Materialart: Online-Ressource
    ISSN: 2234-943X
    Sprache: Unbekannt
    Verlag: Frontiers Media SA
    Publikationsdatum: 2022
    ZDB Id: 2649216-7
    Standort Signatur Einschränkungen Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 2
    Online-Ressource
    Online-Ressource
    Informa UK Limited ; 2023
    In:  Science and Technology of Advanced Materials Vol. 24, No. 1 ( 2023-12-31)
    In: Science and Technology of Advanced Materials, Informa UK Limited, Vol. 24, No. 1 ( 2023-12-31)
    Materialart: Online-Ressource
    ISSN: 1468-6996 , 1878-5514
    Sprache: Englisch
    Verlag: Informa UK Limited
    Publikationsdatum: 2023
    ZDB Id: 2045079-5
    ZDB Id: 2027985-1
    Standort Signatur Einschränkungen Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 3
    In: American Journal of Surgical Pathology, Ovid Technologies (Wolters Kluwer Health), Vol. 48, No. 4 ( 2024-04), p. 406-416
    Kurzfassung: Epstein-Barr virus (EBV)-positive nodal T-cell and NK-cell lymphoma is a rare neoplasm of cytotoxic T-cell or NK-cell lineage. Here, we report 26 cases affecting 14 men and 12 women with a median age of 52 years. All patients presented with disease involving multiple lymph nodes, and 20 of 22 (91%) fully staged patients had advanced Ann Arbor stage disease. Spleen, liver, and bone marrow were involved in 70%, 50%, and 52% of cases, respectively. These patients had a dismal prognosis with a median survival of 30 days. Histologically, lymph nodes were replaced by lymphoma in a diffuse pattern. Lymphoma cells were variable in size and large cell morphology was seen in 62% of cases. The neoplastic cells were CD4-/CD8- in 14 (54%) cases and CD4-/CD8+ in 12 (46%) cases. CD56 was positive in 14 (54%) cases. CD30 was positive in 20 (77%) cases; a strong and diffuse pattern was observed in 14 (54%) cases, mimicking, in part, anaplastic large cell lymphoma (ALCL). CD30 expression was associated with younger age and large cell morphology. In summary, EBV+ nodal T-cell and NK-cell lymphoma is an aggressive disease with a poor prognosis. These neoplasms are heterogeneous at the morphologic and immunophenotypic levels. Diffuse and strong expression of CD30 could potentially lead to a misdiagnosis of ALCL if EBV evaluation is not performed. Distinguishing between EBV+ nodal T-cell and NK-cell lymphoma from ALCL is important because treatment strategy and prognosis differ. CD30 expression offers a potential therapeutic target for patients with this aggressive disease.
    Materialart: Online-Ressource
    ISSN: 0147-5185
    RVK:
    Sprache: Englisch
    Verlag: Ovid Technologies (Wolters Kluwer Health)
    Publikationsdatum: 2024
    ZDB Id: 752964-8
    Standort Signatur Einschränkungen Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 4
    In: Blood, American Society of Hematology, Vol. 142, No. Supplement 1 ( 2023-11-02), p. 5926-5926
    Kurzfassung: Gilteritinib, a potent FMS-like tyrosine kinase 3 (FLT3) inhibitor, was approved for relapsed/refractory (R/R) FLT3 mutated acute myeloid leukemia (AML) patients but still showed limited efficacy. Here, the efficacy and safety of different gilteritinib-based combination therapy (gilteritinib plus hypomethylating agent [HMA] and venetoclax, G+HMA+VEN; gilteritinib plus HMA, G+HMA; gilteritinib plus venetoclax, G+VEN) in 33 R/R FLT3 mutated AML patients were retrospectively analyzed. Composite complete response (CRc) rate (complete response [CR] +CR with partial hematologic recovery [CRh]+CR with incomplete blood count recovery [CRi] ), modified CRc rate (mCRc, CRc+morphologic leukemia-free state [MLFS]), overall survival (OS), duration of remission (DOR), and adverse events were analyzed and compared.The CRc and mCRc rate were 66.7% (12/18) and 88.9% (16/18) in patients who received G+HMA+VEN, which was higher compared with that in G+HMA (CRc: 18.2%, 2/11; mCRc: 45.5%, 5/11) or G+VEN (CRc: 50.0%, 2/4; mCRc: 50.0%, 2/4). The median OS for G+HMA+VEN, G+HMA, G+VEN treatment was not reached, 145.5 days, and 231.0 days, respectively (G+HMA+VEN vs G+HMA, p=0.011). The median DOR for G+HMA+VEN, G+HMA, G+VEN treatment was not reached, 82.0 days, and 77.0 days, respectively (G+HMA+VEN vs G+VEN, p=0.040). Four patients in G+HMA+VEN group received allogenic hematopoietic stem cell transplantation (alloHSCT) after remission exhibited prolonged OS and DOR. The most common grade 3/4 adverse events were cytopenia, febrile neutropenia and pulmonary infection, there were no difference among three groups.In conclusion, our data demonstrated promising response of G+HMA+VEN combination therapy in R/R FLT3 mutated AML patients, and it may consider as an effective bridge to transplantation.
    Materialart: Online-Ressource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Sprache: Englisch
    Verlag: American Society of Hematology
    Publikationsdatum: 2023
    ZDB Id: 1468538-3
    ZDB Id: 80069-7
    Standort Signatur Einschränkungen Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 5
    In: Cancer Cell International, Springer Science and Business Media LLC, Vol. 21, No. 1 ( 2021-12)
    Kurzfassung: Peripheral T-cell lymphoma(PTCL) is a group of lymphoproliferative tumors originated from post-thymic T cells or mature natural killer (NK) cells. It shows highly aggressive clinical behaviour, resistance to conventional chemotherapy, and a poor prognosis. Although a few prognostic models of PTCL have been established in retrospective studies, some high-risk patients still can not be screened out. Therefor we retrospectively studied 347 newly diagnosed PTCL patients and assessed the prognostic role of lymphocyte-monocyte ratio (LMR) and platelet-monocyte ratio (PMR) in the complete response (CR) and survival of PTCL patients. Patients with LMR ≤ 1.68 and PMR ≤ 300 achieved a lower CR rate and a poor survival. In multivariate analysis, LMR ≤ 1.68 (HR = 1.751, 95% CI 1.158–2.647, p  〈  0.05) and PMR ≤ 300 (HR = 1.762, 95% CI 1.201–2.586, p  〈  0.05) were independently associated with short survival. On this basis, a new prognostic model of PTCL was established to screen out high-risk patients. In our "Peripheral Blood Score (PBS)" model, three groups were identified at low risk (178 patients, 51.3%, score 0), intermediate risk (85 patients, 24.5%, score 1), and high risk (84 patients, 24.2%, score 2), having a 1-year OS of 86%, 55.3% and 22.6% (p  〈  0.05), and a 3-year OS of 43.4%, 20% and 13.1% (p  〈  0.05), respectively. Optimal strategies for identifying high-risk patients with PTCL are urgently needed. Our new PBS model is simple, inexpensive and widely available to screen out the high risk patients.
    Materialart: Online-Ressource
    ISSN: 1475-2867
    Sprache: Englisch
    Verlag: Springer Science and Business Media LLC
    Publikationsdatum: 2021
    ZDB Id: 2091573-1
    Standort Signatur Einschränkungen Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 6
    Online-Ressource
    Online-Ressource
    Springer Science and Business Media LLC ; 2023
    In:  Acta Metallurgica Sinica (English Letters) Vol. 36, No. 2 ( 2023-02), p. 266-280
    In: Acta Metallurgica Sinica (English Letters), Springer Science and Business Media LLC, Vol. 36, No. 2 ( 2023-02), p. 266-280
    Materialart: Online-Ressource
    ISSN: 1006-7191 , 2194-1289
    Sprache: Englisch
    Verlag: Springer Science and Business Media LLC
    Publikationsdatum: 2023
    ZDB Id: 2238871-0
    ZDB Id: 1236110-0
    SSG: 6,25
    SSG: 19,1
    Standort Signatur Einschränkungen Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 7
    Online-Ressource
    Online-Ressource
    Informa UK Limited ; 2022
    In:  Hematology Vol. 27, No. 1 ( 2022-12-31), p. 1130-1139
    In: Hematology, Informa UK Limited, Vol. 27, No. 1 ( 2022-12-31), p. 1130-1139
    Materialart: Online-Ressource
    ISSN: 1607-8454
    Sprache: Englisch
    Verlag: Informa UK Limited
    Publikationsdatum: 2022
    ZDB Id: 2035573-7
    Standort Signatur Einschränkungen Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 8
    Online-Ressource
    Online-Ressource
    American Chemical Society (ACS) ; 2015
    In:  Journal of the American Chemical Society Vol. 137, No. 3 ( 2015-01-28), p. 1052-1055
    In: Journal of the American Chemical Society, American Chemical Society (ACS), Vol. 137, No. 3 ( 2015-01-28), p. 1052-1055
    Materialart: Online-Ressource
    ISSN: 0002-7863 , 1520-5126
    RVK:
    RVK:
    Sprache: Englisch
    Verlag: American Chemical Society (ACS)
    Publikationsdatum: 2015
    ZDB Id: 1472210-0
    ZDB Id: 3155-0
    Standort Signatur Einschränkungen Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 9
    In: Blood, American Society of Hematology, Vol. 138, No. Supplement 1 ( 2021-11-05), p. 3395-3395
    Kurzfassung: The outcome of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) have greatly improved in tyrosine kinase inhibitors (TKIs) era and is just moving to a chemo-free era using dasatinib and blinatumomab (Foà R, N Engl J Med. 2020; Ravandi F, Blood. 2019). However, the outcome of T315I/compound-mutated Ph+ ALL patients is dismal (Cortes JE, N Engl J Med. 2013), representing an unmet need. Recently, Scherr et al reported the curative potential of venetoclax-TKIs-dexamethasone in a BCR-ABL+ mouse model (Scherr M, Leukemia. 2019). Here, we firstly reported outcome of 19 T315I/compound-mutated relapsed/refractory (R/R)Ph+ ALL patients treated with venetoclax(100mg d1, 200mg d2, 400mg d3-28), ponatinib (45mg d1-28) and dexamethasone (0.15mg/kg d1-21,0.075mg/kg d22-28)(VPD regimen) (Figure 1A) between January 2020 and May 2021. They had already received a median of 3 lines of salvage therapy. After one cycle, 17 patients (89.5%) achieved CR/CRi [13 minimal residual disease (MRD)--negative by flow cytometry;11 major molecular remission (MMR);8 complete molecular remission (CMR)] (Figure 1B). Subsequently relapse occurred in 1/6 [allogeneic hematopoietic cell transplantation (allo-HSCT) group)] and 7/11 (VDP consolidation group). At a median follow-up of 259 days, the median EFS and OS of patients from the starting VPD treatment was 242 and 400 days. Adverse events of VPD regimen were listed in Figure 1C. Grade 3-4 neutropenia, anemia and thrombocytopenia occurred in 73.7%,36.8% and 52.6% patients. 5.3% and 16% patients have grade 3-4 rash and infection separately. No tumor lysis syndrome or death occurred. 7/19 patients were treated safety outpatient. Moreover, venetoclax had a strong synergistic effect with ponatinib and dexamethasone on inducing apoptosis of primary blast cells and BaF3 cells expressing p190 BCR/ABL with T315I-mutation in vitro, with a combination index of 0.019 when the suppressing rate is 0.05, while the effect was significant decreased when ponatinib was replaced by dasatinib (Figure 1D-F), a prominent change of mitochondrial membrane potential as well as the cleavage of PARP were also observed in triple-combination treatment group (Figure 1G-H). For T315I/compound-mutated Ph+ ALL, VPD regimen exhibited 89.5% CR/CRi rate, with deep molecular remission (57.9% MMR), while ponatinib alone showed 41% hematologic response (Cortes JE, N Engl J Med. 2013), which supported by the preclinical data suggesting TKIs and venetoclax are highly synergistic in BCR-ABL + cells in vitro (Scherr M, Leukemia. 2019). 7/11 and 1/6 patients subsequently relapsed in continuous VPD and allo-HSCT postremission treatment group separately, suggested bridging to allo-HSCT after remission is warranted. Moreover, novel compounds such as blinatumomab showed a preliminary efficacy (Couturier MA, Leuk Lymphoma. 2021). In summary, VPD regimen provides a novel treatment for T315I/compound-mutated R/R Ph+ALL under a complete oral and chemo-free model. A clinical trial also using similar VPD regimen for treatment of R/R Ph+ ALL is ongoing now (Short NJ, Am J Hematol. 2021). Figure 1 Figure 1. Disclosures No relevant conflicts of interest to declare.
    Materialart: Online-Ressource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Sprache: Englisch
    Verlag: American Society of Hematology
    Publikationsdatum: 2021
    ZDB Id: 1468538-3
    ZDB Id: 80069-7
    Standort Signatur Einschränkungen Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 10
    Online-Ressource
    Online-Ressource
    American Society of Hematology ; 2005
    In:  Blood Vol. 106, No. 11 ( 2005-11-16), p. 5371-5371
    In: Blood, American Society of Hematology, Vol. 106, No. 11 ( 2005-11-16), p. 5371-5371
    Kurzfassung: Total parenteral nutrition (TPN) is provided to patients undergoing allogenic hematologic stem cell transplantation (allo-HSCT) to help minimize nutritional consequences of both conditioning regimens as well as complications resulting from the procedure such as GVHD, VOD and so on, and glutamine could to improve the clinical course of patients after transplantation while given with parenteral nutrition as it is considered that it has stimulatory effects on lymphocytes and mucosa cells in vitro. In the study, we investigated the effect of dipeptiven, N(2)-L-Alanyl-L-Glutamine, which has dipeptides as free glutamine is rather unstable and poorly soluble, added to standard TPN preparations on complication and recovery of patients with allo-HSCT. 40 patients who suffered hematologic malignancies and received allo-HSCT were randomly assigned to receive either standard TPN (control group, n=20), or dipeptiven supplemented TPN (DPT group, n=20). The Bu/Cy2 regimen was used in conditioning with Bu (16mg/kg) plus Cy (120mg/kg) and all patients were given mycophenolate mofetil, CsA and MTX to prevent GVHD. The nutritiona support was started about 1 to 12 days after transplantation and 1.5ml/kg.d dipeptiven was added to the DPT group. During the period of nutritiona support, serum albumin, total protein, creatinine, total bilirubin, leukocytes, lymphocytes were monitored, and time to neutrophil engraftment, decrease of body weight, hospital stays, and other data related to hospital infection and acute GVHD were evaluated for all patients. As a result, the levels of serum albumin fell in the two groups on the 7-day, but on the 28-day those in the DPT group returned to normal and were significantly better than those in the control group (P & lt;0.05). The total bilirubin and creatinine concentration did not change much. And lymphocytes of the patients in the DPT group recovered more rapidly than in the control group (P & lt;0.05). There were less cases with clinical infection and microbial colonization in the DPT group than the control group (10 vs 16,11 vs 17, P & lt;0.05). Also days for antibiotic requirements, days of diarrhea, changes of body weight and hospital stays reduced in the DPT group (16.5±10.6d vs 25.4±16.3d, 4.7±4.5d vs 8.2±6.0d, 2.0±2.0kg vs 3.3±1.6kg, 49.2±18.8d vs 58.0±20.2d, P & lt;0.05, respectively). There were no different between the two groups of incidence of acute GVHD. In the conclusion, DPT-supplemented parenteral nutrition was beneficial in allo-HSCT patients for the nutritional status improving, the incidence of infection and damage of intestine, liver diminishing were all reduced, and the incidence of acute GVHD not increasing.
    Materialart: Online-Ressource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Sprache: Englisch
    Verlag: American Society of Hematology
    Publikationsdatum: 2005
    ZDB Id: 1468538-3
    ZDB Id: 80069-7
    Standort Signatur Einschränkungen Verfügbarkeit
    BibTip Andere fanden auch interessant ...
Schließen ⊗
Diese Webseite nutzt Cookies und das Analyse-Tool Matomo. Weitere Informationen finden Sie hier...